What is the recommended empiric therapy for community‑acquired pneumonia for outpatients without comorbidities, for patients with a penicillin allergy, for those with comorbidities or recent antibiotic use, and for hospitalized patients?

Empiric Therapy for Community-Acquired Pneumonia

For outpatients without comorbidities, use amoxicillin 1g every 8 hours or a macrolide (azithromycin or clarithromycin); for penicillin allergy, use a macrolide or doxycycline; for patients with comorbidities or recent antibiotic use, use a respiratory fluoroquinolone alone OR combination therapy with a β-lactam plus macrolide; for hospitalized non-ICU patients, use a respiratory fluoroquinolone OR β-lactam plus macrolide; for ICU patients, use a β-lactam (ceftriaxone, cefotaxime, or ampicillin-sulbactam) plus either azithromycin or a respiratory fluoroquinolone. 1, 2

Outpatient Management

Previously Healthy, No Recent Antibiotics

The 2019 IDSA/ATS guidelines prioritize amoxicillin 1g every 8 hours as first-line therapy, representing a shift from older macrolide-first approaches 2. This recommendation stems from inpatient studies demonstrating efficacy despite lack of atypical coverage, combined with excellent safety profile and reduced resistance concerns.

Alternative options:

• Macrolide (azithromycin 500mg day 1, then 250mg daily OR clarithromycin 500mg twice daily) 1, 2
• Doxycycline 100mg twice daily 1, 2

Critical caveat: In regions with macrolide-resistant S. pneumoniae ≥25%, avoid macrolide monotherapy 1

Penicillin Allergy

Use a macrolide (azithromycin or clarithromycin) OR doxycycline 100mg twice daily 1, 2

For hospitalized patients with penicillin allergy, use a respiratory fluoroquinolone (levofloxacin 750mg daily, moxifloxacin 400mg daily, or gemifloxacin 320mg daily) 1

Comorbidities (COPD, diabetes, heart/renal/liver disease, malignancy) WITHOUT Recent Antibiotics

Two equally acceptable approaches:

1. Respiratory fluoroquinolone monotherapy (levofloxacin 750mg daily, moxifloxacin 400mg daily, or gemifloxacin 320mg daily) - Strong recommendation 1, 2

2. Combination therapy:

   • Amoxicillin-clavulanate 875mg/125mg twice daily OR 2000mg/125mg twice daily
   • PLUS macrolide (azithromycin or clarithromycin) OR doxycycline 100mg twice daily 1, 2

Recent Antibiotic Use (within 3 months)

This is a critical risk factor for drug-resistant S. pneumoniae and requires different antibiotic class selection 3.

Recommended regimens:

• Respiratory fluoroquinolone alone (if no recent fluoroquinolone use) 3
• Advanced macrolide PLUS high-dose amoxicillin (1g three times daily) 3
• Advanced macrolide PLUS amoxicillin-clavulanate 3

Key principle: Select a different antibiotic class than recently used to avoid resistance 3

Hospitalized Patients - Non-ICU

Two equally effective regimens (Level I evidence for both): 1

1. Respiratory fluoroquinolone monotherapy (levofloxacin 750mg daily or moxifloxacin 400mg daily)

2. β-lactam PLUS macrolide combination:

   • β-lactam: ceftriaxone, cefotaxime, or ampicillin (ertapenem for selected patients with gram-negative risk factors)
   • PLUS macrolide: azithromycin or clarithromycin
   • Doxycycline is an acceptable macrolide alternative (Level III evidence) 1

For penicillin allergy: Use respiratory fluoroquinolone 1

Important note: Combination therapy has strengthened evidence for severe CAP and may reduce mortality compared to monotherapy in hospitalized patients 1

ICU Patients

Standard ICU CAP (No Pseudomonas Risk)

Use β-lactam PLUS either azithromycin (Level II) OR fluoroquinolone (Level I) - Strong recommendation 1

Preferred β-lactams:

• Ceftriaxone
• Cefotaxime
• Ampicillin-sulbactam

For penicillin allergy: Respiratory fluoroquinolone PLUS aztreonam 1

Pseudomonas Risk Factors Present

Risk factors include severe structural lung disease (bronchiectasis), recent hospitalization, recent broad-spectrum antibiotics 3

Use antipseudomonal β-lactam PLUS one of the following: 1

• Ciprofloxacin OR levofloxacin 750mg, OR
• Aminoglycoside PLUS azithromycin, OR
• Aminoglycoside PLUS antipneumococcal fluoroquinolone

Antipseudomonal β-lactams:

• Piperacillin-tazobactam
• Cefepime
• Imipenem
• Meropenem

For penicillin allergy with Pseudomonas risk: Aztreonam PLUS levofloxacin 750mg 3

MRSA Risk

Add vancomycin OR linezolid if community-acquired MRSA suspected (recent influenza, necrotizing pneumonia, hemoptysis) 1

Critical Implementation Points

Route of administration:

• Most hospitalized non-severe patients can receive oral antibiotics if no contraindications 4
• Switch from IV to oral when hemodynamically stable, improving clinically, able to ingest medications 1
• No need for inpatient observation on oral therapy before discharge 1

Duration:

• Minimum 5 days for patients afebrile 48-72 hours with clinical stability 1
• Recent 2025 data supports 3 days for patients stabilized by day 3, 5 days if stable by day 5,7 days for uncomplicated cases 5
• Extend to 14-21 days for Legionella, Staphylococcus, or gram-negative bacilli 4

Common pitfalls to avoid:

• Using macrolide monotherapy in areas with high macrolide resistance (≥25%) 1
• Repeating the same antibiotic class recently used within 3 months 3
• Delaying first antibiotic dose in ED - should be given while still in ED 1
• Continuing IV antibiotics when oral route appropriate - increases costs and complications 4